Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 18.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 18.0 Contact Hours.
To earn an additional 4.0 AMA PRA Category 1 Credits™, attend the CAR T Preconference Workshop.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 18.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Accreditation/Designation of Credit for Nursing Track (Clinical Pearls for Practice Educational Session and Networking for Advanced Practitioners)
This activity is approved for 1.75 contact hour(s) of continuing education (which includes 1.75 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 19023560. This activity was planned in accordance with AANP Accreditation Standards and Policies.
Acknowledgement of Commercial Support
This activity is supported by educational grants from AbbVie Inc., Acerta Pharma – A member of the AstraZeneca Group, Adaptive Biotechnologies, Celgene Corporation, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Jazz Pharmaceuticals, Inc., NewLink Genetics, Novartis Pharmaceuticals Corporation, Rigel Pharmaceuticals, Inc., Seattle Genetics, Inc., and Takeda Oncology.
23rd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma
23rd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma -- Call for Poster Abstracts!
The 23rd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma (HEM) Program Chairs invite you to submit your abstracts for this year's International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma to be held February 28 through March 3, 2019, at the Eden Roc Miami.
The Abstract Portal is now closed.
All poster abstract submissions must be made electronically through the Congress' online abstract submission system.
Your abstract should be a short description of your work and contain all the elements necessary to define your goals and results to the reader. Authors will be required to disclose all financial relationships through the online system, helping to ensure quality and unbiased presentations. The formal poster session is not designated for credit.
Share your research or best practices with your peers. Categories of submission include:
- Acute lymphoblastic leukemia
- Acute myeloid leukemia
- Chronic lymphocytic leukemia
- Chronic myeloid leukemia
- Hodgkin lymphoma
- Non-Hodgkin lymphoma
- Multiple myeloma
- Myelodysplastic syndromes
- Myeloproliferative neoplasms
- Other blood cell disorders, including ITP
- Other, including preclinical studies
The Program Chairs will evaluate the scientific quality of the submitted abstracts on the basis of the following criteria: novelty of the research, significance of the findings, and clarity. Incomplete abstracts will not be reviewed. Please note that we will consider case series, but are not accepting single-patient case reports.
Notification of acceptance or regret will be delivered via e-mail to the presenter(s) of each poster abstract by early February. Please note that an author is required to be present during the poster session.
If accepted for presentation, abstracts and posters will be available for viewing online on the 2019 Congress website during and after the conference. The posters will be displayed for the length of the conference. The presentation at the 23rd Annual International Congress on Hematologic Malignancies® should reflect the submitted abstract-abstract title, authorship, and content of the presentation at the 23rd Annual International Congress on Hematologic Malignancies® must match the submitted abstract.
All presenters must register to attend the 23rd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma. Please click here to register.
- Complete the abstract template provided on the 2018 Congress website.
- Limit is 2500 characters (abstract body, including spaces and table).
- Upload full abstract or poster where prompted.
Components of the Abstract Body-Limit: 2500 Characters (1 table allowed)
- Background/Significance -What was the problem and why was it important? What knowledge are you building on? What was the intent or goal of the study? What did you want to learn?
- Materials and Methods -What was the trial design? What was the sample? What instruments were used? How were data collected and analyzed?
- Results -What were the findings?
- Conclusions -What do the findings mean?
Please submit any questions pertaining to abstract submissions to firstname.lastname@example.org using the subject line "HEM Abstract QUESTION."
Author Consent and Waiver of Claims
Each Abstract Author agrees and certifies that he or she:
- Waives any and all claims against Physicians' Education Resource®, LLC, sponsor of the 23rd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma, and any review arising out of or relating to the abstract submission and review process, including but not limited to peer review and the grading of abstracts.
Note: The hotel is expected to sell out, and it is likely to do so before the discounted cutoff date of 2/5/2019. Reservations may be made online here.